NIH announces meeting about the first-in-human use of gene editing via CRISPR/Cas9 technology

The recombinant DNA Advisory committee is holding a meeting on June 21-22 2016 on CRISPR/Cas 9 use in humans with a T cell immunotherapy protocol that involves the use of CRISPR/Cas9 to edit two genes in T cells also modified to express T cell receptors targeting myeloma, melanoma, and sarcoma tumor cells.  The meeting is open to the public or can be attended remotely by the webcast link here on the days of the meeting.  More info here  

We have less than 30 days to go to raise our goal for our proposed experiment, please support our project with a donation and/or pass the word.

http://experiment.com/anti-viral